-

Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital

Article 223-16 - Règlement Général de l’Autorité des marchés financiers

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:

Theraclion (Paris:ALTHE):

Listed on Euronext Growth Paris
PEA PME eligible
ISIN Code: FR0010120402
Website: www.theraclion.com

Voting rights:

Date

Total number of shares of Theraclion

Total number of theoretical voting rights of Theraclion (1)

Total number of real voting rights of Theraclion (2)

30/06/2026

73 123 311

89 137 355

87 570 061

(1) Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares stripped of voting rights, in accordance with Article 223-11 of the AMF's General Regulation

(2) Actual voting rights correspond to the total number of voting rights exercisable at the Annual General Meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares less shares stripped of voting rights.

About Theraclion

Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound.
High-Intensity Focused Ultrasound (HIFU) requires no incisions or operating room, leaves no scars and allows patients to immediately resume their daily activities. The HIFU method concentrates therapeutic ultrasound toward an internal focal point from outside the body.
Theraclion is developing Sonovein®, a HIFU robotic platform for the treatment of varicose veins, CE-marked under MDR (EU 2017/745), with the potential to replace millions of surgical procedures each year. To date, Sonovein® has been adopted by more than a dozen centres worldwide and has been used in more than 4,000 procedures. In the United States, Sonovein® is not yet available for sale.

Based in Malakoff (Paris), the Theraclion team consists of approximately 35 people.

For more information, please visit www.theraclion.com and follow us on LinkedIn.

Theraclion is listed on Euronext Growth Paris
Eligible for the PEA-PME scheme
Ticker: ALTHE - ISIN Code: FR0010120402
LEI: 9695007X7HA7A1GCYD29

Contacts

Theraclion
Martin Deterre
Chief Executive Officer
contact@theraclion.com

Theraclion

BOURSE:ALTHE
Release Versions
EnglishFrench

Contacts

Theraclion
Martin Deterre
Chief Executive Officer
contact@theraclion.com

More News From Theraclion

Theraclion Announces the Evolution of Its Board of Directors

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), announces that Mr. Yann Duchesne has decided not to stand for re-election as Director and Chairman of the Board following the General Meeting held on June 18, 2026, positions he had held since January 24, 2022. The Company, all members of the Board o...

Theraclion Secures Key U.S. Reimbursement Milestone for Sonovein® With AMA CPT Editorial Panel Approval of a New Category III CPT Code

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: Theraclion (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing a platform for non-invasive therapy using high intensity focused ultrasound (HIFU) for the treatment of varicose veins (the “Company”), today announced that the American Medical Association (AMA) CPT Editorial Panel has approved the creation of a new Category III CPT code for non-invasive (HIFU) treatment of varicose veins, performed using Sonovein®. The new code...

Theraclion Announces First Clinical Deployment of Sonovein® in Hainan, China

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402 – Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive therapy using high intensity focused ultrasound (HIFU) for the treatment of varicose veins, announces a significant milestone in its China expansion strategy with the deployment of a SONOVEIN® system at Boao Super Hospital in Hainan Province supported by its Joint Venture with its strategic partner Inner Mongolia Furui Medical S...
Back to Newsroom